IN8bio (INAB) COO Rochlin received 60,000 units
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Kate Rochlin (President and COO at IN8bio Inc., INAB) reported that they received 60,000 units on May 9, 2026.
- Reporting person
- Rochlin Kate
- Role
- President and COO
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| May 9, 2026 | Grant or award (A) | Employee Stock Option (right to buy)On 60,000 Common Stock1 | +60,000 | - | - | 60,000 direct |
Holdings before and after
- Employee Stock Option (right to buy): 0 to 60,000 direct
Footnotes from the filing
- 1. Twenty-five percent (25%) of the shares subject to the option shall vest on each of November 9, 2026, May 9, 2027, November 9, 2027 and May 9, 2028, subject to the Reporting Person continuing to provide service through each such date.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Rochlin report in this INAB Form 4?
Kate Rochlin (President and COO at IN8bio Inc., INAB) reported that they received 60,000 units on May 9, 2026.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for INAB
Across the 12 sessions after earlier INAB headlines, the stock closed higher 3 times and lower 9 times, with a median move of 2.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | INAB | SPY |
|---|---|---|---|
| May 8, 2026 | IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights | -1.2% | +0.8% |
| May 6, 2026 | IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences | -2.5% | +1.4% |
| Apr 6, 2026 | IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | -2.1% | +0.5% |
| Mar 13, 2026 | IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026 | -1.0% | -0.6% |
| Feb 24, 2026 | IN8bio to Present at TD Cowen 46th Annual Health Care Conference | +2.6% | +0.7% |
| Feb 9, 2026 | IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer | +0.5% | +0.5% |
Earlier insider filings at INAB
- May 12, 2026SEC Form 4 filed by Director Fairbairn Emily
- May 12, 2026SEC Form 4 filed by CHIEF FINANCIAL OFFICER Mccall Patrick
- May 12, 2026SEC Form 4 filed by Director Greenwood Luba
- May 12, 2026SEC Form 4 filed by Director Brandt Peter C.
- May 12, 2026SEC Form 4 filed by Director Graff Jeremy R.
Quantisnow market dataNASDAQ
INAB
IN8bio Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2021
Get push alerts for INAB
Full INAB profile on Quantisnow Follow INAB and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time